After a median follow-up of 10 years, anastrozole demonstrated superiority over tamoxifen in terms of disease-free survival (DFS), time to recurrence and distant recurrence, although no significant difference was observed in overall survival (OS).351 Another meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) analyzed the benefits of 5-year treatment with an aromatase inhibitor or tamoxifen in 31,920 postmenopausal women with ER-positive early breast cancer. The gene discussed is CYP19A1; the disease is breast carcinoma.